PDCD1 and neoplasm: To directly assess the role of T cells in reducing tumor growth in Bcl9-shRNA tumors during anti-PD-1 treatment, we depleted CD8+ T cells using a CD8-neutralizing antibody and subsequently examined the effect of Bcl9-shRNA combined with anti-PD-1 on tumor growth.